Búsqueda de: xience

Si no está conforme con los resultados, inténtelo de nuevamente.
Chronic Ischemic cardiopathy

TCT 2025 | TUXEDO-2: Ultra-Thin Struts Versus Xience in Diabetic Patients with Multivessel Disease

It is well known that diabetic patients undergoing PCI often present with more extensive coronary artery disease,...
Dr. Andrés Rodríguez -
Ir
Coronary disease

Diffuse Coronary Artery Disease: One-Year 48mm XIENCE Skypoint Outcomes

Long 48mm Stent XIENCE Skypoint in the treatment of diffuse CAD Long coronary artery lesions often involve complex...
solaci -
Ir
Antiplatelet

XIENCE SHORT DAPT | Ideal DAPT Period for Patients at High Risk of Bleeding

In patients at high risk of bleeding undergoing coronary stenting with a Xience stent, 1-to-3-month DAPT period...
solaci -
Ir
CORONARY DISEASE

EuroPCR 2021 | CASTLE: Orsiro vs Xience Guided by Intravascular Imaging

According to the CASTLE trial, the Orsino stent—a biodegradable, ultrathin, sirolimus-eluting stent—provides the same results at 12 months...
solaci -
Ir
Antiplatelet

Xience Receives CE Mark for Short and Ultrashort DAPT Schemes

Dual antiplatelet therapy (DAPT) one month after angioplasty with Xience stent was approved in Europe for patients...
solaci -
Ir
Antiplatelet

TCT 2020 | Xience in Favor of Short Dual Antiaggregation Therapy with High Bleeding Risk

Following with aspirin alone after a short period of dual antiaggregation therapy (DAPT), 1 to 3 months,...
solaci -
Ir
Coronary disease

Theoretical Advantages Translated into Worst Clinical Outcomes: Synergy vs. Xience

New data from a real-world registry soon to be published in J Am Coll Cardiol Intv suggest...
solaci -
Ir
Coronary disease

EuroPCR 2019 | Stent Firehawk Continues to Show Good Results at 2 Years vs. Xience

This device, an abluminal groove-filled biodegradable-polymer sirolimus-eluting stent manufactured in China, showed very similar efficacy and safety...
solaci -
Ir